about
sameAs
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsImpact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1HIV broadly neutralizing antibody targetsDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesStructures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designDelineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationUse of alternate coreceptors on primary cells by two HIV-1 isolatesInsensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype BAdherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South AfricaRandomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infectionGeographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysisCorrection: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-AnalysisInternational network for comparison of HIV neutralization assays: the NeutNet report IIEstablishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study.International network for comparison of HIV neutralization assays: the NeutNet report.Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trialResistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveysDurable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study.Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesIsolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.AIDS-related mycoses: the way forward.Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting.Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesCharacterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infectionRegional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-Gp120 aptamer.A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1Specificity of the autologous neutralizing antibody responseEmergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
P50
Q24629582-EF7568E7-E23B-49B2-B931-A03187016816Q24635002-F148F46C-B9BE-41BC-B351-0956419249D2Q24792432-F81AC009-574C-4015-A9FC-DB05FD08FAACQ27022652-3D52B377-076E-4FCF-A697-A19428B4B436Q27025177-E4ACF56D-61C4-40B1-B481-D032212C02ABQ27026662-D1619D72-9001-442F-B173-572D644BD250Q27644515-FAC0B183-EE11-4F90-B4AC-3890BD5F6753Q27644634-397A9D01-19CB-4DE2-BBA8-BF572ACFCAECQ27684578-D26EF187-BBA5-436F-82FB-4E93875920FDQ28259404-0119AFA3-5568-4241-B19B-DB4F48D85A9DQ28469023-4C74C6E6-F59B-490F-A374-A39ED832F19DQ28477379-DAEDFAF2-36A8-47DA-A465-895020308FABQ28478848-290674C1-13FA-4392-8037-C45B5E1B9A77Q28545866-5CA8D0DA-DFCA-4E3E-958D-FE362B0EE5BAQ28547717-6F2054D7-88D0-4DC0-BB56-395BF7E7803AQ28730045-2DC14FB1-2D92-4C62-B289-A9510178975DQ33328477-634667ED-ECF5-46B5-A50D-1900C59E5F72Q33410826-39087CD2-96C4-465A-8F11-62648564D66BQ33504604-4A293E26-188D-480A-99BE-DB7F093F8908Q33605273-60F86259-6923-400B-88C5-A19840A07B36Q33684387-81511819-328E-40C4-BBCD-B7DEF082CCC6Q33714130-1B85E4EF-2A27-46D2-A264-9BD4E296DE92Q33739249-A9F03EA3-E4C4-4E6F-85A0-92FAF90A98E9Q33791635-E62EBC7E-8C25-49B9-876F-1105CFFBECE7Q33805619-143F9823-E2D7-4CAC-85F8-AC90671339B7Q33814942-7DB879AB-04E4-493F-A6E5-4006A010893FQ33911935-39EE6D10-A883-465F-B8B6-1B6E12B4A82CQ33912373-F9E855C5-29AD-47C3-B733-AE96F63FC12DQ33952538-CE23081E-AC5E-4BC9-B8E6-D8678D8A4693Q34030928-9EF814AF-7983-4A9E-A84C-D1F6BE90ED04Q34042758-8A3F3A37-F58A-48E6-B928-CD3E7A038739Q34112568-6694AA6B-AF47-430D-9EA0-2BB6DCD2A488Q34177732-1EA98288-2A00-4C61-93D6-96E271443152Q34300812-DD6E3711-9967-4FC4-BBA6-EB6BD104CC65Q34332009-365ED2F8-E584-4C36-9029-A99C08056B11Q34352000-7439D2D2-4850-4002-A687-AD09382CBA7EQ34362343-928A3CED-B456-4246-AF21-4695EC818058Q34396912-518B13F0-F6E4-4EF2-9C8B-FFFD52E2A438Q34415389-FE5F9579-2C9F-4B97-9DC2-B5A246FD64A4Q34424673-98BAD2D5-4AD7-405E-826F-277EC01988CE
P50
description
investigador
@es
researcher
@en
virologe uit Zuid-Afrika
@nl
name
Lynn Morris
@ast
Lynn Morris
@en
Lynn Morris
@es
Lynn Morris
@nl
type
label
Lynn Morris
@ast
Lynn Morris
@en
Lynn Morris
@es
Lynn Morris
@nl
prefLabel
Lynn Morris
@ast
Lynn Morris
@en
Lynn Morris
@es
Lynn Morris
@nl
P106
P21
P31
P496
0000-0003-3961-7828